logo
PMI U.S. Hosts Clinic on Legal Support for Veterans

PMI U.S. Hosts Clinic on Legal Support for Veterans

Business Wire05-05-2025
WASHINGTON--(BUSINESS WIRE)--On Friday, May 2, 2025, PMI U.S. hosted experts from the University of Florida Levin College of Law, the Rocky Mountain Veterans Advocacy Project in Colorado and the University of Arizona James E. Rogers College of Law. Panelists shared their practice experience, case studies and policy recommendations to help address common challenges that military families face.
With support from PMI U.S. funding, lawyers and law students from the clinics offer individualized guidance to veterans on navigating complex issues, such as completing Department of Veterans Affairs (VA) benefit applications and accessing resources like mental health services.
Case studies covered:
How insights from an individual case in Florida led to new national policies, practices and legislative proposals.
Expanding outreach to Navajo Nation veterans in Colorado and improving access to benefits through legal and mental health evaluations.
Increasing access and legal assistance for Arizona veterans in rural and Tribal areas.
PMI U.S. contributions in 2024 and 2025 will provide nearly $1 million in funding to veterans' advocacy law clinics to help veterans and their families access the benefits they've earned.
About PMI U.S.
Philip Morris International Inc. is headquartered in Stamford, Connecticut, and its U.S. affiliates (collectively, 'PMI U.S.') employ more than 2,500 people. PMI U.S. is on a mission to improve public health by providing the 45 million nicotine consumers in the U.S. — 30 million of which still smoke traditional cigarettes — with better alternatives. Since 2008, PMI has invested more than $14 billion globally to develop and commercialize FDA-authorized smoke-free products for legal-age nicotine consumers. PMI U.S. operates smoke-free product manufacturing facilities, including Swedish Match North America's Owensboro, Kentucky plant that makes ZYN nicotine pouches and Triaga's facility in Wilson, North Carolina, that produces HEETS as part of the IQOS heated tobacco system. Swedish Match North America has a regional office in Richmond, Virginia.
U.S. marketing practices support 21+ access only
PMI U.S. is committed to responsible marketing practices focused on limiting access to adults 21 years of age and older. PMI U.S. does not use social media influencers in the U.S. or people under the age of 35 — or who appear to be under the age of 35 — in marketing materials. PMI U.S. also employs independent age-verification systems, such as Double Verify, to direct digital advertising to those over 21, and owned digital platforms are age-gated at the point of access and restricted to current nicotine consumers who are 21+. Swedish Match North America is a Manufacturer Advisory Council member of the We Card Program, a national nonprofit serving retailers of age-restricted products. PMI is also a founding board member and investor in TruAge®, a free retail technology that provides stores with a more accurate method of age verification, including the ability to better detect fake IDs, to ensure access is limited to those 21+.
U.S. mission to improve public health through smoke-free products
Because adult nicotine consumer preferences differ, PMI U.S. is working to offer a range of smoke-free options for adults 21+. Since 2008, PMI has invested over $14 billion to develop, scientifically substantiate and commercialize innovative smoke-free products. In 2022, PMI acquired Swedish Match — a leader in oral nicotine delivery — creating a global smoke-free champion led by the ZYN and IQOS brands.
IQOS is authorized by the FDA as a modified risk tobacco product, meaning the FDA has found it appropriate for the promotion of public health. Although IQOS heatsticks are not risk-free and contain nicotine, which is addictive, studies show that because the device heats tobacco instead of burning it, it significantly reduces the production of and exposure to harmful chemicals compared to conventional cigarettes for adults who smoke and who switch to IQOS completely.
In 2025, the FDA authorized all 20 Swedish Match ZYN nicotine pouch products currently sold in the U.S., making ZYN the only FDA-authorized nicotine pouch on the market to help adults who use cigarettes or traditional tobacco products completely switch. The FDA has authorized Swedish Match's General snus as a modified risk tobacco product. Currently, PMI U.S. holds more than 80 percent of modified risk tobacco product authorizations and more than 45 percent of premarket tobacco product authorizations.
Commitment to corporate social responsibility
PMI U.S. has contributed approximately $25 million to charitable causes since 2022, amplifying the good work of organizations already active within communities through both financial contributions and volunteering. PMI U.S.'s philanthropy efforts include supporting military veterans and military spouses, disaster prevention and relief and grassroots economic development. PMI U.S. helped form United to Safeguard America from Illegal Trade, a coalition of nearly 100 national and state brand enforcement experts, law enforcement agencies, academics and leading business organizations working to combat illegal trade. USA-IT has trained more than 36,000 law enforcement officials.
For more information, please visit www.pmi.com/us/ and www.pmiscience.com. 'PMI' refers to the Philip Morris International family of companies. 'PMI U.S.', 'we', 'our', and 'us' refer to PMI's U.S. businesses.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Global Kratom Coalition Applauds FDA Action Against Hydroxie and Expects Broader Crackdown Against Synthetic Opioids Like 7
Global Kratom Coalition Applauds FDA Action Against Hydroxie and Expects Broader Crackdown Against Synthetic Opioids Like 7

Associated Press

time14 minutes ago

  • Associated Press

Global Kratom Coalition Applauds FDA Action Against Hydroxie and Expects Broader Crackdown Against Synthetic Opioids Like 7

FDA action aligns with a growing chorus of scientists, public health experts, and advocates warning against the public health risk associated with the proliferation of 7 The Global Kratom Coalition (GKC) today commended the U.S. Food and Drug Administration (FDA) for issuing a comprehensive and forceful warning letter to Hydroxie, LLC, a seller of synthetic 7-hydroxymitragynine (otherwise known as '7') products falsely marketed as dietary supplements, shots, and drink mixes. The GKC hailed the move as a critical step in addressing these products that masquerade as natural dietary supplements but are actually unapproved new drugs. 'This warning letter is a major step in a broader effort to remove dangerous '7' products from store shelves and online marketplaces,' said Walker Gallman, Legislative Director of the Global Kratom Coalition. 'These actions should protect consumers and safeguard the integrity of the dietary supplement marketplace. It should result in a cascade of warnings to other 7 makers.' In the June 25, 2025, letter , the FDA identified multiple violations of the Food, Drug, and Cosmetic Act, citing Hydroxie's products as both unapproved new drugs and adulterated food. The FDA noted that Hydroxie's 7 products—including its 'Hydroxie 15mg 7-OH Tablets,' 'Hydroxie Red Shots,' and 'Hydroxie 7-OH Drink Mix"—are marketed with drug claims and contain an ingredient not generally recognized as safe. 'Your Hydroxie 15mg 7-OH Tablets, Hydroxie Red 15mg Tablets... are drugs as defined by section 201(g)(1) of the FD&C Act... because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease,' the FDA stated in the letter. 'Based on our review... the use of 7-OH in conventional food does not satisfy the criteria for GRAS status... [and] raises serious concerns about potential harm associated with 7-OH,' the agency warned. 'This is a watershed moment,' said Gallman. 'The FDA has now publicly and definitively recognized that products like Hydroxie's, which are made up of synthetically boosted and highly concentrated levels of 7-hydroxymitragynine, are deceptively marketed as dietary supplements or conventional foods and are illegal. They are not kratom products; they are not dietary supplements; they are not legal; they are unapproved drugs and adulterated foods masquerading as legal, natural products.' FDA Warning Letter Addresses Persistent 'Bad Actors' Damaging Industry The GKC has long warned that certain actors in the marketplace are undermining public trust in the dietary supplement industry by selling synthetically enhanced or adulterated 7 products, often under the guise of 'all natural' or 'dietary supplement' or as 'kratom'. However, these products are marketed by the companies that sell them and the advocacy organizations that support them ( Holistic Alternate Recovery Trust (HART) and 7-Hope Alliance ) as drugs to treat chronic pain and opioid use disorder. The FDA's letter made clear that: 7 has not been evaluated by the FDA for safe use. Without formal safety evaluation, consumers are left exposed to unknown risks from products that have never undergone rigorous scientific review. The FDA has received adverse event reports associated with 7. Reports of harm linked to 7 include serious side effects such as liver toxicity, seizures, and respiratory issues, underscoring the need for immediate regulatory scrutiny. 7 has opioid-like effects and poses unique safety concerns. Because concentrated, synthetic 7 is a novel, potent opioid receptor agonist, its presence in unregulated consumer products raises red flags about addiction, misuse, and overdose. 'We urge the FDA and state regulators to continue down this path,' said Gallman. 'The longer these products are on the market, the greater the threat to public safety.' A Growing Chorus of Concern About Synthetic 7-Hydroxymitragynine Products The FDA warning letter also adds to a growing chorus of scientists, researchers, and industry stakeholders who have issued concerns about 7 products. In reaction to the FDA warning letter on social media, Dr. Christopher R. McCurdy, PhD, from the University of Florida College of Pharmacy said , 'The FDA is taking action on semi-synthetic kratom alkaloid derivatives, and this is exactly what we count on the FDA to do! These non-kratom products need to be removed from the market as they are no different from the many synthetic cannabinoids that made up 'spice' and caused harm to many … These novel chemicals synthesized from kratom extracts are potent opioids and a public health threat as currently marketed. They might be beneficial if pursued through the same pathways that all novel drugs gain approval.' In a statement released last week, Dr. C. Michael White, Pharm.D., FCP, FCCP, FASHP, a pharmacist, distinguished professor of pharmacy practice at the University of Connecticut School of Pharmacy, and Kratom Consumer Advisory Council chair said: 'Selling potent opioid receptor-stimulating 7 products in gas stations, convenience stores, and smoke shops in unlimited quantities within arm's reach of candy bars and energy drinks is a public health recipe for disaster. It allows a whole new generation of consumers to potentially get hooked on opioids, and we know where that leads.' In late 2024, leading kratom researchers at Johns Hopkins University and the University of Florida issued urgent warnings about proliferation of 7 products and for its potential for abuse, dependence, severe withdrawal , and even respiratory depression, dangers that run directly counter to it being marketed as a treatment for opioid addiction. GKC Committed to Transparency and Science The Global Kratom Coalition will continue to encourage and support federal and state regulators to investigate vendors who make false or misleading claims about their products, particularly those promoting unapproved drugs disguised as dietary supplements. About Global Kratom Coalition The Global Kratom Coalition is an alliance of kratom consumers, experts, and industry leaders dedicated to protecting access to kratom while advancing scientific research, driving consumer education, and developing robust regulations to protect consumers. For more information, visit Media Contact Patrick George +1 916-202-1982 [email protected] ### SOURCE: Global Kratom Coalition Copyright 2025 EZ Newswire

DoubleVerify, IAS develop attention measurement solutions for Snap
DoubleVerify, IAS develop attention measurement solutions for Snap

Yahoo

time18 minutes ago

  • Yahoo

DoubleVerify, IAS develop attention measurement solutions for Snap

This story was originally published on Marketing Dive. To receive daily news and insights, subscribe to our free daily Marketing Dive newsletter. Media measurement platforms DoubleVerify and Integral Ad Science (IAS) have unveiled products to measure users' attention on Snapchat, providing marketers with insights into how consumers engage with their ads, per separate announcements. DoubleVerify's product, DV Authentic Attention for Social, launches first with Snap, while additional platform integrations are set for later this year. The solution combines ad exposure data with eyes-on-screen ad signals from Lumen Research. The product from IAS, Snap Attention Measurement, leverages artificial intelligence-powered media quality data and also uses Lumen's eye-tracking technology for a bespoke Snapchat attention score within its IAS Signal platform. In today's media-saturated world, the question is not how you reach consumers, but whether they are even paying attention at all. The two products from DoubleVerify and IAS are designed to provide advertisers with more insight into whether their ads are keeping viewers interested. DV Authentic Attention for Social offers three main metrics: ad focus, which evaluates the ability for the ad to capture eye gaze; dwell time, which measures how long an ad holds a users' attention, measured by seconds the focus each ad receives; and attention index, which offers an overall measure of attention on Snap and empowers brands to benchmark their results against peer performance within their vertical. DV Authentic Attention for Social is a key component of the company's Media AdVantage Platform, which combines campaign outcomes measurement, ad optimization and media verification to maximize performance. The launch of the solution marks an expanded partnership between Snap and DoubleVerify, which already offers fraud, brand suitability and viewability measurement on Snapchat. The new product is available globally on Snapchat and is set to expand to other platforms throughout 2025, per release details. Snap Attention Measurement, the new product from IAS, will offer similar insights, giving advertisers a bespoke Snapchat attention score within IAS Signal, IAS's reporting platform, so they can better understand media performance and engagement. The tool combines Lumen eye-tracking and IAS's AI-powered media quality data to form the attention score. The latest advertiser offerings from Snap are part of its ongoing efforts to attract more brands to its platform. For example, Snap announced updates to its Sponsored Snaps product and a suite of AI-powered solutions in May. Snap reported $1.36 billion in revenue in Q1 2025, representing 14% year over year growth, per its latest earnings statement. Recommended Reading TikTok looks past last-click as part of measurement suite expansion

Irish service sector growth slows markedly in June, PMI shows
Irish service sector growth slows markedly in June, PMI shows

Yahoo

timean hour ago

  • Yahoo

Irish service sector growth slows markedly in June, PMI shows

DUBLIN (Reuters) -Ireland's service sector expansion slowed down markedly in June as softer output, hiring activity and a decline in new export orders led to one of the weakest monthly readings in more than four years of unbroken growth, a survey showed on Thursday. The AIB Global S&P Purchasing Managers' Index (PMI) fell to 51.5 from 54.7 in May, the weakest growth rate since January 2024 and the third-lowest mark since the sector's sharp rebound from COVID-19 lockdowns began in March 2021. The sector also outperformed the average for the wider euro zone - a 50.0 flash reading - by a tighter margin than during much of that run. The waning momentum contrasted with the Irish manufacturing PMI, which grew at the fastest pace in more than three years last month and at a sharper rate than services for just the second time during that period. New service sector business growth also slowed, with international demand falling for the first time in 20 months, which some firms attributed to weaker markets in the U.S. and Europe and ongoing global trade tensions. Employment growth continued but at a reduced pace and the level of outstanding business also decreased for the first time since the start of 2024. There was some relief for customers with the prices charged by service firms rising at the slowest rate in more than four years while the service providers themselves remained optimistic about future growth, albeit sentiment remained close to April's post-pandemic low. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store